(Q36066004)

12 August 2017

1 reference

title

Emerging human papillomavirus vaccines. (English)

1 reference

12 August 2017

Neil D Christensen

1

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 February 2005

1 reference

Expert Opinion on Emerging Drugs

12 August 2017

published in

1 reference

12 August 2017

volume

10

1 reference

12 August 2017

issue

1

1 reference

12 August 2017

page(s)

5-19

1 reference

Papillomaviruses and cancer: from basic studies to clinical application

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Heterogeneity of papillomaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Classification of papillomaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

The causal relation between human papillomavirus and cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Epidemiologic classification of human papillomavirus types associated with cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Natural history of cervicovaginal papillomavirus infection in young women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Cervical Cancer Screening: From the Papanicolaou Smear to the Vaccine Era

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Centrosomes, genomic instability, and cervical carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Telomerase activation by the E6 gene product of human papillomavirus type 16.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

A population-based study of vaginal human papillomavirus infection in hysterectomized women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Anogenital neoplasia in AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Evidence for a causal association between human papillomavirus and a subset of head and neck cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Human papillomavirus type 16 and 18 DNA in oral squamous cell carcinoma and normal mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

HPV infections and tonsillar carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Human papillomavirus (HPV) in head and neck cancer. An association of HPV 16 with squamous cell carcinoma of Waldeyer's tonsillar ring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Viral etiology of juvenile- and adult-onset squamous papilloma of the larynx

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Human papillomavirus infections in children: the potential role of maternal transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Epidermodysplasia verruciformis. Immunological and nonimmunological surveillance mechanisms: role in tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Prevailing papillomavirus types in non-melanoma carcinomas of the skin in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

The immunology of animal papillomaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Established and potential strategies against papillomavirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Placebo-controlled trial of indole-3-carbinol in the treatment of CIN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

A controlled trial of a human papillomavirus type 16 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

HPV6b virus like particles are potent immunogens without adjuvant in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Prevention of cervical cancer through papillomavirus vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Amino acid residues in the carboxy-terminal region of cottontail rabbit papillomavirus E6 influence spontaneous regression of cutaneous papillomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Recurrent respiratory papillomatosis: altered CD8(+) T-cell subsets and T(H)1/T(H)2 cytokine imbalance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

IMMUNIZATION OF RABBITS TO INFECTIOUS PAPILLOMATOSIS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Immunization with a pentameric L1 fusion protein protects against papillomavirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Vaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine papillomavirus-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Intracutaneous vaccination of rabbits with the cottontail rabbit papillomavirus (CRPV) L1 gene protects against virus challenge .

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Intra-epithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Therapeutic immunisation with COPV early genes by epithelial DNA delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Intracutaneous vaccination of rabbits with the E6 gene of cottontail rabbit papillomavirus provides partial protection against virus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Intracutaneous DNA vaccination with the E8 gene of cottontail rabbit papillomavirus induces protective immunity against virus challenge in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Ubiquitin-fused and/or multiple early genes from cottontail rabbit papillomavirus as DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

HLA expression in pre-invasive cervical neoplasia in relation to human papilloma virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

ORAL PAPILLOMATOSIS OF RABBITS: A VIRUS DISEASE

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

CUTANEOUS PAPILLOMATOSIS IN CATTLE AND OTHER ANIMALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Comparison of HPV DNA vaccines employing intracellular targeting strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

CD8+ T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumour

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-Expressing sindbis virus replicon particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Flow cytometric quantitation of the protective efficacy of dendritic cell based vaccines in a human papillomavirus type 16 murine challenge model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Naked RNA vaccine controls tumors with down-regulated MHC class I expression through NK cells and perforin-dependent pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

Dendritic Cells as Carriers for a Cytotoxic T-Lymphocyte Epitope-Based Peptide Vaccine in Protection Against a Human Papillomavirus Type 16-Induced Tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.1.5

21 January 2018

Identifiers

DOI

10.1517/14728214.10.1.5

1 reference

12 August 2017

1 reference